CD276 and hepatocellular carcinoma: In agreement, B7-H3 expression was more prevalent among patients with de novo metastatic HCC compared to subjects with localized disease (96% vs. 76.3%, p = 0.036) [78] and B7-H3+ patients had significantly restricted median overall survival (mOS) following surgery compared to B7-H3− counterparts (19.2 vs. 37.3 months, respectively; p = 0.009) [78].